Dr. Paul Bolno has served as President and CEO of Wave since 2013 and oversaw the company’s initial public offering in 2015. During his tenure as President and CEO, Paul has grown Wave into a leading RNA medicines company, overseen the development of the company’s proprietary PRISM® platform, and built a diversified pipeline of preclinical and clinical programs supported by scalable, in-house manufacturing capabilities.
In addition to his current role at Wave, Paul serves as Chairman of the Board of Directors to ExpressionEdits, and as Chairman of the Scientific Advisory Group for the Nucleic Acid Therapy Accelerator (NATA) in the United Kingdom.
Prior to joining Wave, he was Vice President, Worldwide Business Development—Head of Asia BD and Investments, as well as Head of Global Neuroscience BD, at GlaxoSmithKline (GSK). He also served as a Director of Glaxo Wellcome Manufacturing, Pte Ltd. in Singapore. Paul joined GSK as Vice President, Business Development for the Oncology Business Unit, where he helped establish GSK’s global oncology business and served as a member of the Oncology Executive Team, Oncology Commercial Board and Cancer Research Executive Team. Prior to GSK, he served as Director of Research at Two River LLC, a healthcare private equity firm.
Paul earned a medical degree from MCP-Hahnemann School of Medicine and an MBA from Drexel University. He was a general surgery resident and cardiothoracic surgery postdoctoral research fellow at Drexel University College of Medicine.
What is Paul Bolno's net worth?
The estimated net worth of Paul Bolno is at least $922.02 thousand as of August 22nd, 2025. Bolno owns 121,000 shares of WAVE Life Sciences stock worth more than $922,020 as of December 4th. This net worth evaluation does not reflect any other investments that Bolno may own. Additionally, Bolno receives a salary of $1,130,000.00 as CEO at WAVE Life Sciences. Learn More about Paul Bolno's net worth.
What is Paul Bolno's salary?
How do I contact Paul Bolno?
Has Paul Bolno been buying or selling shares of WAVE Life Sciences?
Paul Bolno has not been actively trading shares of WAVE Life Sciences in the last ninety days. Most recently, Paul Bolno sold 217,351 shares of the business's stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $10.10, for a transaction totalling $2,195,245.10. Following the completion of the sale, the chief executive officer now directly owns 121,000 shares of the company's stock, valued at $1,222,100. Learn More on Paul Bolno's trading history.
Who are WAVE Life Sciences' active insiders?
Are insiders buying or selling shares of WAVE Life Sciences?
In the last twelve months, insiders at the sold shares 8 times. They sold a total of 467,533 shares worth more than $4,461,142.90. The most recent insider tranaction occured on November, 13th when Director Adrian Rawcliffe sold 16,115 shares worth more than $109,420.85. Insiders at WAVE Life Sciences own 24.0% of the company.
Learn More about insider trades at WAVE Life Sciences. Information on this page was last updated on 11/13/2025.
